Clinical practice recommendations for the management of Alport syndrome: a joint statement of the Korean Society of Nephrology and the Korean Society of Pediatric Nephrology
Childhood Kidney Diseases · 2026-10-30 · 30 (3) · 164-174
DOI: 10.3339/ckd.26.030 ↗At a glance
Journal article in Childhood Kidney Diseases, published online on 2026-10-30. Written by Ji Hyun Kim and 8 co-authors. Institution: Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. 49 references. The full text is freely available in PubMed Central. Funded by: Korean Nephrology Research Foundation.
Abstract (original language)
Purpose
Alport syndrome (AS) is a hereditary kidney disorder characterized by progressive hematuria, proteinuria, and kidney failure, frequently accompanied by hearing loss and ocular abnormalities. Although blockade of the renin-angiotensin system (RAS) is established as the firstline therapy, additional pharmacological interventions have been explored. To formulate evidence-based recommendations tailored to the Korean healthcare setting, the Genetic Kidney Disease Study Group of the Korean Society of Nephrology conducted a systematic review evaluating four therapeutic strategies: RAS blockade, cyclosporine, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter 2 inhibitors (SGLT2i).
Methods
The quality of evidence and strength of recommendations were assessed using the Grading of Recommendations Assessment, Development and Evaluation framework.
Results
The review confirmed that early initiation of RAS blockade delays progression to kidney failure and improves long-term survival, with the greatest benefit when initiated at the stage of microscopic hematuria or microalbuminuria. In contrast, evidence supporting cyclosporine, MRAs, and SGLT2i remains limited, primarily derived from small observational studies with short follow-up and heterogeneous populations. Although cyclosporine and MRAs have demonstrated short-term reductions in proteinuria, neither has shown sustained renoprotective effects, and cyclosporine is associated with a substantial risk of nephrotoxicity. Evidence regarding SGLT2i is inconsistent, with insufficient data on longterm efficacy in AS.
Conclusions
Accordingly, these guidelines strongly recommend early RAS blockade as the cornerstone of AS, while no recommendations are made for routine use of cyclosporine, MRAs, or SGLT2i. Well-designed clinical trials are needed to expand therapeutic options and improve longterm outcomes in AS.
Subjects
Author keywords
Authors and institutions
- Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
- Department of Pediatrics, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Truewords Dialysis Clinic, Incheon, Republic of Korea.
- Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Transplantation Center, Seoul National University Hospital, Seoul, Republic of Korea.
- Department of Pediatrics, Seoul National University Children's Hospital, Seoul, Republic of Korea.
Funding
- Korean Nephrology Research Foundation
Cite
APA
Kim, J. H., Hwang, Y. H., Kang, E., Kang, H. G., Park, D. A., Shin, H. S., Cho, M. H., Ahn, Y. H., & Alport Syndrome Guideline Development Group (2026). Clinical practice recommendations for the management of Alport syndrome: a joint statement of the Korean Society of Nephrology and the Korean Society of Pediatric Nephrology. Childhood Kidney Diseases, 30(3), 164-174. https://doi.org/10.3339/ckd.26.030
Vancouver
Kim JH, Hwang YH, Kang E, Kang HG, Park DA, Shin HS, et al. Clinical practice recommendations for the management of Alport syndrome: a joint statement of the Korean Society of Nephrology and the Korean Society of Pediatric Nephrology. Childhood Kidney Diseases. 2026;30(3):164-174. doi:10.3339/ckd.26.030
BibTeX
@article{Kim2026,
author = {Kim, Ji Hyun and Hwang, Young-Hwan and Kang, Eunjeong and Kang, Hee Gyung and Park, Dong Ah and Shin, Ho Sik and Cho, Min Hyun and Ahn, Yo Han and Alport Syndrome Guideline Development Group, Alport Syndrome Guideline Development Group},
title = {Clinical practice recommendations for the management of Alport syndrome: a joint statement of the Korean Society of Nephrology and the Korean Society of Pediatric Nephrology},
journal = {Childhood Kidney Diseases},
year = {2026},
volume = {30},
number = {3},
pages = {164--174},
doi = {10.3339/ckd.26.030}
}
EUVIMED